APPLICATION OF IL-1 RECEPTOR PEPTIDE INDIVIDUALLY OR IN COMBINATION WITH D-ALA-GLN OCTADETHYL ETHER AS A THERAPEUTIC

摘要

1. The combination of the peptides Lys-Ile-Cys-Ile-Arg-Ile-Gln-Ile-Ser-OH and octadecyl ether D-Ala-Gln or their salts or hydrates. ! 2. The combination according to claim 1, where the peptides are contained in combination in an amount of from 30% by weight to 70% by weight to 70% by weight to 30% by weight. ! 3. The combination according to claim 1 for use in a medicinal product. ! 4. The use of the peptide Lys-Ile-Cys-Ile-Arg-Ile-Gln-Ile-Ser-OH or a combination according to claim 1, 2 or 3 for the preparation of a pharmaceutical composition for the treatment and / or prevention of a malignant tumor, autoimmune diseases fibrosis, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and blood vessel diseases and metabolic diseases. ! 5. The use of the peptide according to claim 4, where the infectious disease is selected from Mycobacterium tuberculosis infection and infectious diseases caused by Mycobacterium tuberculosis infection selected from infectious diseases of the lung, central nervous system, lymphatic system, circulatory system, genitourinary system, bones, joints and skin . ! 6. The use of the peptide Lys-Ile-Cys-Ile-Arg-Ile-Gln-Ile-Ser-OH for the preparation of the composition for oral administration to newborns, toddlers and / or preschool children. ! 7. The use of the peptide Lys-Ile-Cys-Ile-Arg-Ile-Gln-Ile-Ser-OH to obtain a lyophilized composition or a buffer liquid composition. ! 8. A pharmaceutical composition comprising the Lys-Ile-Cys-Ile-Arg-Ile-Gln-Ile-Ser-OH peptide or a combination according to claim 1, at least in conjunction with one pharmaceutically acceptable carrier, cryoprotectant, lyoprotector, excipient and / or diluent. ! 9. The pharmaceutical composition of claim 8 in the form of a lyophilisate or a liquid buffer solution. ! 10. The pharmaceutical composition